单药塞利尼索治疗急性髓系白血病的1期临床试验
这项1期剂量递增研究纳入95例复发或难治性急性髓系白血病(AML)患者,于2013年1月至2014年6月接受每周两次塞利尼索治疗。推荐2期剂量为60 mg(约35 mg/m2),4周为一周期;可评估患者中14%达客观缓解,缓解者中位无进展生存期和总生存期均显著优于未缓解者。
要点
- 推荐2期剂量为60 mg(约35 mg/m2),每周两次,4周为一周期。
- 81例可评估患者中14%达客观缓解,31%骨髓原始细胞较基线下降≥50%。
- 客观缓解者中位无进展生存期5.1个月 vs 未缓解者1.3个月(P=.008,HR 3.1)。
核心结论
- 塞利尼索作为单药在复发或难治性AML患者中安全,并为后续2期临床开发提供了依据。
研究设计与样本
- 1期剂量递增研究,纳入95例复发或难治性AML患者,于2013年1月至2014年6月入组,接受21天或28天周期内4、8或10次塞利尼索给药。
主要发现
- AML患者中最常见不良事件为1级或2级全身性和胃肠道毒性,一般可通过支持治疗管理。
- 唯一发生率>5%的非血液学3/4级不良事件为乏力(14%)。
- 未报告剂量限制性毒性或蓄积性毒性证据。
- 81例可评估患者中14%达客观缓解,31%骨髓原始细胞较基线下降≥50%。
- 达客观缓解者中位无进展生存期5.1个月 vs 未缓解者1.3个月(P=.008,HR 3.1),中位总生存期9.7个月 vs 2.7个月(P=.01,HR 3.1)。
关键数值与推荐
- 推荐2期剂量为60 mg(约35 mg/m2),每周两次,4周为一周期,基于安全性和有效性数据的总体评估确定。
临床怎么用
- 原文结论为塞利尼索作为单药在复发或难治性AML患者中安全,并已据此开展后续2期临床开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study was initiated to examine the safety and efficacy of selinexor in patients with advanced hematological malignancies. Ninety-five patients with relapsed or refractory acute myeloid leukemia (AML) were enrolled between January 2013 and June 2014 to receive 4, 8, or 10 doses of selinexor in a 21- or 28-day cycle. The most frequently reported adverse events (AEs) in patients with AML were grade 1 or 2 constitutional and gastrointestinal toxicities, which were generally manageable with supportive care. The only nonhematological grade 3/4 AE, occurring in >5% of the patient population, was fatigue (14%). There were no reported dose-limiting toxicities or evidence of cumulative toxicity. The recommended phase 2 dose was established at 60 mg (∼35 mg/m2) given twice weekly in a 4-week cycle based on the totality of safety and efficacy data. Overall, 14% of the 81 evaluable patients achieved an objective response (OR) and 31% percent showed ≥50% decrease in bone marrow blasts from baseline. Patients achieving an OR had a significant improvement in median progression-free survival (PFS) (5.1 vs 1.3 months; P = .008; hazard ratio [HR], 3.1) and overall survival (9.7 vs 2.7 months; P = .01; HR, 3.1) compared with nonresponders. These findings suggest that selinexor is safe as a monotherapy in patients with relapsed or refractory AML and have informed subsequent phase 2 clinical development. This trial was registered at www.clinicaltrials.gov as #NCT01607892.
引用
- Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017. PMID: 28336527. doi:10.1182/blood-2016-11-750158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。